SCHEMBL1481176

SCHEMBL1481176

CCCCOc1ccc(-c2ccc(/C=C/c3nc(-c4ccc(Cl)cc4Cl)cn3Cc3ccc(OC(F)(F)F)cc3)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 1/20 0.40
ATP4A P20648 3/20 0.38
ATP4B P51164 3/20 0.38
CNR1 P21554 5/20 0.36
MARS1 P56192 1/20 0.35
PTPN1 P18031 1/20 0.34
FFAR1 O14842 1/20 0.34
CYP2C9 P11712 1/20 0.34
SCN5A Q14524 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
PPARA Q07869 1/20 0.33
AHR P35869 1/20 0.33
PDGFRB P09619 1/20 0.33
THRB P10828 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
PGGT1B P53609 1/20 0.33
PPARD Q03181 1/20 0.32
ALOX5 P09917 1/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481178 1.00 AGER (0.40) AGERATP4AATP4BCNR1MARS1
SCHEMBL1481418 0.90 FFAR4 (0.48) MARS1FFAR1CYP2C9SCN5AFFAR4
SCHEMBL1481421 0.90 FFAR4 (0.48) MARS1FFAR1CYP2C9SCN5AFFAR4
SCHEMBL1483322 0.90 FFAR4 (0.39) CNR1MARS1FFAR1CYP2C9SCN5A
SCHEMBL1483320 0.90 FFAR4 (0.39) CNR1MARS1FFAR1CYP2C9SCN5A
SCHEMBL1483691 0.88 MARS1 (0.39) CNR1MARS1SCN5AFNTAFNTB
SCHEMBL1483692 0.88 MARS1 (0.39) CNR1MARS1SCN5AFNTAFNTB
SCHEMBL1481541 0.87 CNR1 (0.44) AGERCNR1
SCHEMBL1481539 0.87 CNR1 (0.44) AGERCNR1
SCHEMBL1481425 0.86 RARB (0.42) AGERCNR1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ AGER 1249/4885ATP4A 2140/4885ATP4B 2971/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ AGER 1249/4885ATP4A 2140/4885ATP4B 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.